



Helping the Hard-Core Smokers Suffering from Pulmonary Diseases

Jean Perriot*

Department of Respiratory Medicine, University of Auvergne, France

*Corresponding author: Jean Perriot, Department of Respiratory Medicine, University of Auvergne, Centre Emile Roux, 11 rue Vaucanson, 63100, Clermont-Ferrand, France, Tel: 06 86 96 88 69; E-mail: jean.perriot@puy-de-dome.fr

Received date: Sep 25, 2017; Accepted date: Sep 29, 2017; Published date: Oct 06, 2017

Copyright: © 2017 Perriot J. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution and reproduction in any medium, provided the original author and source are credited.

Citation: Perriot J (2017) Helping the Hard-Core Smokers Suffering from Pulmonary Diseases. J Respir Med 1: e101.

Editorial

One on two smokers who smokes all his lifetime will die from a disease related to tobacco use. Every year, tobacco smoking is responsible for about 6 million deaths worldwide; it could kill 1 billion people during the 21st century [1]. Most of the smokers have in common to be highly dependent on nicotine, a significant level of cigarette consumption and great difficulty to quit smoking; these hard-core smokers, strongly inhaling tobacco smoke and quite often users of others psychoactive substances (cannabis, cocaine) are particularly vulnerable to respiratory diseases related to this exposure [2]. The leading cause of lung cancer worldwide in both males and females is tobacco smoking [3]. It has been shown that smoking has a detrimental effect on survival, it increases the risk of post-operative complications in the case of resection surgery, decreases the efficacy and tolerance of medical treatments (chemotherapy and radiotherapy), in smoker the risk of second primary malignant tumor is increased [4]. On the contrary stopping smoking at the time of diagnosis improves cancer prognosis and patients' quality of life [5]. Smoking is a main cause of chronic obstructive pulmonary disease (COPD) [6]. A recent review of the literature has highlighted that there is a high prevalence of tobacco smoking among patients suffering from COPD [7]. Smoking cessation reduces all at once decline of lung function, frequency of exacerbations and improves response to bronchodilators and inhaled corticosteroids [8]. Smoking has a negative impact on many respiratory diseases and infections. The pathophysiological mechanisms by which tobacco smoke is a cause of asthma is poorly understood; however smoking cessation is a component of the management of the disease [9]. Tobacco smoke impairs the lung defense mechanisms against infections [10]. Compared with people who do not smoke, active or passive smokers have approximately two fold risk of infection if exposed to *Mycobacterium tuberculosis* and a significant risk of having active TB in the case of infection; TB smokers have an increased risk of death [11], these findings lead to recommend the systematic management of smoking cessation in TB smokers. A study highlighted, in a setting of care well organized including antiretroviral therapy free of charge, that the number of life-years lost (at 35-year-old) in association with smoking in HIV-infected smokers compared to HIV-infected abstinent of tobacco smoking were 12, 3 [12]. The pulmonologist holds a prominent place in the diagnosis of respiratory diseases. Lung cancer, COPD, asthma, pulmonary tuberculosis and many other pulmonary diseases are caused or worsened by smoking. At the forefront of healthcare professionals, pulmonologists must be involved in helping patients to stop smoking. Smoking cessation interventions are not complicated nor time-

consuming; all increase abstinence rates [13]: simple advice to stop smoking, minimal intervention in 5 steps (the 5 As: ask, advise, assess, assist, arrange), behavioral and cognitive strategies to reinforce motivation to quit smoking and ability to control craving, medication treatments for nicotine dependence (nicotine replacement therapies, varenicline or bupropion) in dependent smokers decrease withdrawal syndrome and craving. The inventory of respiratory diseases of whose smoking is the main cause, risk or aggravating factor, as well as gains in abandoning tobacco smoking highlights the need for the pulmonologists to be involved in smoking cessation.

References

1. Jha P (2009) Avoidable global cancer deaths and total deaths from smoking. *Nat Rev Cancer* 9: 655-664.
2. Perriot J, Underner M, Peiffer G, Le Houezec J, Samalin L, et al. (2012) Helping the 'hard-core' smokers. *Rev Mal Respir* 29: 448-461.
3. Islami F, Torre LA, Jemal A (2015) Global trends of lung cancer mortality and smoking prevalence. *Transl Lung cancer Res* 4: 327-338.
4. Dautzenberg B (2012) Methods and results of smoking cessation in cancer smoker's. *Bull Cancer* 99: 1007-1015.
5. Parsons A, Daley A, Begh R, Aveyard P (2010) Influence of smoking cessation after diagnosis of early stage of lung cancer on prognosis: Systematic review of observational studies with meta-analysis. *BMJ* 340: b5569.
6. Forey BA, Thornton AJ, Lee PN (2011) Systematic review with meta-analysis of the epidemiological evidence relating smoking to COPD, chronic bronchitis and emphysema. *BMC Pulm Med* 11: 36.
7. Tonnesen P (2013) Smoking cessation and COPD. *Eur Respir Rev* 22: 37-43.
8. Jimenez-Ruiz CA, Andreas S, Lewis KE, Tonnesen P, Van Schayck CP, et al. (2015) Statement on smoking cessation in COPD and other pulmonary diseases and in smokers with comorbidities who find it difficult to quit. *Eur Respir J* 46: 61-79.
9. Underner M, Perriot J, Peiffer G, Meurice JC (2015) Influence of tobacco smoking on the risk of developing asthma. *Rev Mal Respir* 32: 110-137.
10. Arcavi L, Benowitz NL (2004) Cigarette smoking and infection. *Arch Intern Med* 164: 2206-2216.
11. Zellweger JP, Cattamanchi A, Sotgiu G (2015) Tobacco and tuberculosis: Could we improve tuberculosis outcomes by helping patients to stop smoking? *Eur Respir J* 45: 583-585.
12. Helleberg M, Afzal S, Kronborg G, Larsen CS, Pedersen G, et al. (2013) Mortality attributable to smoking among HIV-1-infected individuals: A nationwide, population-based cohort study. *Clin Infect Dis* 56: 727-734.
13. Aubin HJ, Luquiens A, Berlin I (2014) Pharmacotherapy for smoking cessation: Pharmacological principles and clinical practice. *Br J Clin Pharmacol* 77: 324-336.